<DOC>
	<DOCNO>NCT01528787</DOCNO>
	<brief_summary>In double-masked , vehicle-controlled , dose-response study , subject randomize receive Netarsudil ( AR-13324 ) Ophthalmic Solution 0.01 % , 0.02 % , 0.04 % vehicle ( one eye ) , q.d . ( AM ) x 7 day . The first dose last dose administer clinic . Ocular safety ocular hypotensive efficacy evaluate clinic throughout study .</brief_summary>
	<brief_title>Study Netarsudil ( AR-13324 ) Patients With Elevated Intraocular Pressure</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>1 . 18 year age great . 18 year age great . 2 . Diagnosis open angle glaucoma ( OAG ) ocular hypertension ( OHT ) . 3 . Unmedicated ( postwashout , p.r.n . ) IOP ≥ 24 mm Hg one eye 08:00 hour , ≥ 21 mm Hg 10:00 , 12:00 16:00 hour postwashout measurement ( Visit 1 ) . 4 . Corrected visual acuity eye +1.0 logMAR good ETDRS eye ( equivalent 20/200 ) . 5 . Able willing give sign informed consent follow study instruction . Ophthalmic : Either eye 1 . Intraocular pressure &gt; 36 mm Hg 2 . Known hypersensitivity component formulation topical anesthetic , ( benzalkonium chloride , etc . ) 3 . Ocular trauma within past six month , ocular surgery laser treatment within past three month . 4 . Evidence ocular infection , inflammation , clinically significant blepharitis conjunctivitis baseline ( Visit 1 ) , history herpes simplex keratitis . 5 . Contact lens wear within 30 minute instillation study medication . 6 . Ocular medication kind within 30 day Visit 2 , exception ) ocular hypotensive medication ( must wash accord provided schedule ) , b ) lid scrub ( may use prior , Visit 2 ) c ) lubricate drop dry eye ( may use throughout study ) , 7 . Clinically significant ocular disease ( e.g . corneal edema , uveitis , severe keratoconjunctivitis sicca ) might interfere study , include glaucomatous damage severe washout ocular hypotensive medication one month judge safe ( e.g. , advance glaucomatous optic nerve head visual field loss ) . 8 . Any abnormality prevent reliable applanation tonometry either eye . Study eye : 9 . Glaucoma : pseudoexfoliation pigment dispersion component , history acute angleclosure glaucoma , close narrow angle upon gonioscopy . Note : Previous laser peripheral iridotomy NOT acceptable . 10 . Previous glaucoma intraocular surgery laser procedure ALT , SLT MLT , well refractive procedure RK , LASIK , PRK , collagen cross link . 11 . Central corneal thickness great 600 μm . General/Systemic : 12 . Clinically significant abnormality laboratory test screen , recognize subject fasting time draw blood . 13 . Clinically significant systemic disease ( e.g. , uncontrolled diabetes , myasthenia gravis , hepatic , renal , cardiovascular endocrine disorder ) might interfere study . 14 . Participation investigational study within past 30 day . 15 . Changes systemic medication study could substantial effect IOP within 30 day prior screen , anticipate study . 16 . Due status preclinical safety program , woman childbearing potential pregnant , nursing , plan pregnancy , use medically acceptable form birth control . An adult woman consider childbearing potential unless one year postmenopausal three month postsurgical sterilization . All female childbearing potential must negative urine pregnancy test result screen examination must intend become pregnant study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Intraocular pressure</keyword>
	<keyword>visual field</keyword>
	<keyword>Ocular hypertension open angle glaucoma</keyword>
</DOC>